Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Leukemia, Myeloid, Acute 3Unspecified Adult Solid Tumor, Protocol Specific 1Prostatic Neoplasms 1Primary Myelofibrosis 1Polycythemia Vera 1

Interventions

fludarabine phosphate 29Peripheral Blood Stem Cell Transplantation 26Cyclophosphamide 25ruxolitinib 22Busulfan 21Tacrolimus 16Whole-Body Irradiation 15Mycophenolic Acid 14Methotrexate 13Cyclosporine 12Antilymphocyte Serum 11Hydroxyurea 10Aspirin 9fludarabine 8Filgrastim 8Melphalan 7Etoposide 7Decitabine 7peginterferon alfa-2a 6Imatinib Mesylate 6Cytarabine 611-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 6givinostat hydrochloride 5givinostat 5Radiotherapy 5Prednisone 5Carboplatin 5Biopsy 5Topotecan 4Thiotepa 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Polycythemia Vera × SB939 compound × Clear all
NCT02267278 2019-06-12

Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)

M.D. Anderson Cancer Center

Phase 2 Completed
25 enrolled 8 charts
Myeloid

Polycythemia Vera, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡